MediWound (NASDAQ:MDWD) COO Sells $51,137.36 in Stock

MediWound Ltd. (NASDAQ:MDWD) COO Shmuel Hess sold 3,958 shares of the company’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shmuel Hess also recently made the following trade(s):

• On Wednesday, August 26th, Shmuel Hess sold 1,865 shares of MediWound stock. The stock was sold at an average price of $13.00, for a total value of $24,245.00.

MediWound Stock Performance

Shares of MediWound stock opened at $12.66 on Monday. MediWound Ltd. has a 12 month low of $12.52 and a 12 month high of $20.30. The firm has a market capitalization of $162.71 million, a P/E ratio of -7.03 and a beta of 0.15. The business has a fifty day simple moving average of $14.16 and a two-hundred day simple moving average of $15.62.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%.The business had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. Analysts predict that MediWound Ltd. will post -2.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MDWD. Quarry LP purchased a new position in MediWound in the 4th quarter worth about $26,000. BNP Paribas Financial Markets boosted its holdings in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares during the last quarter. California State Teachers Retirement System grew its stake in shares of MediWound by 281.4% in the second quarter. California State Teachers Retirement System now owns 2,014 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 1,486 shares during the period. Russell Investments Group Ltd. grew its stake in shares of MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 649 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares during the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

Wall Street Analysts Forecast Growth

MDWD has been the topic of a number of analyst reports. Wall Street Zen cut MediWound from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of MediWound in a report on Thursday, May 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $33.00.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.